Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (October 2023)
23 slides from Painchek's investor presentation, Oct 31, 2023
Slide 1: Investor webinar presentation - ASX announcement
ASX ANNOUNCEMENT 31 October 2023 Investor webinar presentation - Wednesday, 31 October 2023 Further to the webinar announcement made on 30th October 2023, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring applicat
Slide 2: Quarterly Update October 2023
For personal use only Quarterly Update October 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 1 |
Slide 3: Our purpose is to give a voice to people who cannot reliably verbalise their pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 4: The evolution of pain assessment
THE EVOLUTION OF PAIN ASSESSMENT Legacy Pain For personal use only PainChek® Assessment Tools “The PainChek app, which I see as a welcome evolutionary development of my past work, was introduced to improve pain management practices by ensuring an evidence-based assessment of pain could be made at th
Slide 5: The PainChek Universal App: quick and easy operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION AI based micro-facial pain expression analysis: For personal use only A medical • 3 second scan of patient face device in • recognises 9 micro-facial expressions indicative of pain your pocket Guided Digital questionnaire checklist: • guides the
Slide 6: The breadth of PainChek's global market opportunity
THE BREADTH OF PAINCHEK’s GLOBAL MARKET OPPORTUNITY For personal use only 400M pre-verbal children1 25-42% of hospital beds occupied by people with dementia4,5 57M people living with dementia >150M expected by 20502,3 1. Ecology Communications Group. www.ecology.com/birth-death-rates 4. Tsai, I. P.,
Slide 7: PainChek well positioned to exploit large global market opportunities
PAINCHEK WELL POSITIONED TO EXPLOIT LARGE GLOBAL MARKET OPPORTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET 6 MILLION BEDS 1 UP TO 10X AGED 400M PRE-VERBAL ~$1Bn ANNUALLY 4 & CARE MARKET 2 CHILDREN - 150M ANNUALLY TO $300M ANNUAL FIRST TIME PARENTS 3 ARR 2 1.
Slide 8: PainChek around the world and across Australia
PAINCHEK AROUND THE WORLD…AND ACROSS AUSTRALIA 77,000 LICENCES, 1200 AGED CARE FACILITIES ACROSS 3 CONTINENTS Canada For personal use only • Initial RAC sales now in place and implemented • Exploring additional European Union (EU) Aged Care and Home Japan Care partners for North • Targeting RAC beds
Slide 9: Consecutive quarter of double-digit licence growth and strong pipeline
4 th C O N S E C U T I V E Q U A R T E R O F D O U B L E - D I G I T L I C E N C E GROWTH AND STRONG PIPELINE For personal use only Global - Contracted Licences 90,000 77,000 contracted licences with an ARR of 80,000 +91% p.a. 77,037 $3.7M once fully implemented 70,007 70,000 64,163 10% increase on
Slide 10: Strong ARR growth at high gross margins
STRONG ARR GROWTH AT HIGH GROSS MARGINS Global - ARR $M For personal use only 4.00 $3.7 $3.4 3.50 +92% p.a. 92% increase in ARR1 over the prior year $3.1 3.00 SAAS business model with 70-85% gross 2.50 $2.4 % margins2 on annual licences $1.9 2.00 85% retention rate of on annual renewals 1.50 Rapid U
Slide 11: Consistent growth in utility
CONSISTENT GROWTH IN UTILITY For personal use only Cum ulative Num ber of PainChek ® Assessm ents 3,500,000 Over 3.4 million global pain assessments 3,000,000 conducted on the PainChek platform +119% p.a. 2,500,000 115% increase in global pain assessments over the previous year in Aged Care alone 2,
Slide 12: PainChek across Australia
PAINCHEK ACROSS AUSTRALIA AGED CARE’s MOST POPULAR DIGITAL CLINICAL TOOL Aged Care • PainChek commercial licences cover more than 57,000 beds and 800 aged care homes, approx. 30% of total AU market and growing with a For personal use only current retention rate of 85%. • UCQ becomes PCK’s largest cl
Slide 13: PainChek's growing UK footprint
PAINCHEK’S GROWING UK FOOTPRINT • PainChek commercial licences in UK aged care now cover ~21,500 bed licences, 400+ care homes across 93 organisations • New clients in October include BUPA UK – initial 500 bed license pilot agreement across 8 homes agreement with the potential extension for up to Fo
Slide 14: Scottish Care Inspectorate PainChek 1st phase outcomes
S C O T T I S H C A R E I N S P E C T O R A T E P A I N C H E K - 1 st P H A S E O U T C O M E S "We welcome the use of innovation and technology to help support people to experience the best possible care.” “This device should enable more appropriate use of medication and improved quality of life f
Slide 15: St Michael's Health Group - PainChek's 1st Canadian commercial client
ST MICHAEL'S HEALTH GROUP- P A I N C H E K ’ s 1 ST C A N A D I A N C O M M E R C I A L C L I E N T “Our search for the latest advancements in For personal use only FEEDBACK aged care led us to implement PainChek at St. Michael’s Health Group. We consider ourselves lucky that we came across PainChek
Slide 16: Market partnerships and drivers for USA & Canada
MARKET PARTNERSHIPS AND DRIVERS FOR USA & CANADA For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN 2024 NORTH AMERICAN LONG TERM CARE PointClickCare: PainChek integrated with MARKET OPPORTUNITY PointClickCare leading long term care provider in USA & Canada – providin
Slide 17: PainChek Infant progress
PAINCHEK INFANT PROGRESS THREE STEP STRATEGY TARGETING MARKET OF 400M PRE-VERBAL CHILDREN For personal use only Direct to Consumer Health Care Professional New AI vocalisation Marketing reference studies & centers feature • Initial parent market testing • European infant pain • Completion of new com
Slide 18: PainChek Infant: making infant pain visible and audible
PAINCHEK® INFANT Making Infant Pain Visible…and Audible For personal use only 1. 2. 3. 4. 5. 1 Parent or Caregiver PainChek® Infant Parent or Caregiver PainChek® Infant Facial Parent or Caregiver uses hears an Vocalisation technology intervenes and treats technology measures PainChek® Infant to meas
Slide 19: PainChek upcoming catalysts
PAINCHEK UPCOMING CATALYSTS For personal use only Continued acceleration of sales and ARR Complete FDA studies to obtain US growth within RAC, Retirement and Home FDA De Novo clearance in Q2 CY 24 Care setting in ANZ, UK, Canada and new EU opportunities in CY 24 Enter global hospital market sector L
Slide 20: Corporate summary
CORPORATE SUMMARY For personal use only Top shareholders % Financial information Peters Investments Proprietary Ltd 8.4% Share price (20 October 2023) A$0.045 Founders 5.4% Shares on issue 1,406.3m Board & key staff 3.8% Market capitalisation A$63.3m Cash (30 September 2023) A$3.7m Unlisted options/
Slide 21: Contact
For personal use only Quarterly Update October 2023 CONTACT Philip Daffas, CEO & MD philip.daffas@painchek.com PAINCHEK LTD | ASX:PCK 20 |
Slide 22: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 23: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit